Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy
Although considerable progress has been made in the field of cancer chemotherapy, there remains a significant unmet medical need, with a requirement to move away from traditional cytotoxics and explore novel, smarter chemotherapeutic approaches. One such example of the smart chemotherapy approach is...
Main Authors: | Thomas Mehrling, Daniel Soltis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-02-01
|
Series: | Antibodies |
Subjects: | |
Online Access: | http://www.mdpi.com/2073-4468/7/1/11 |
Similar Items
-
Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
by: Christoph Mamot, et al.
Published: (2012-11-01) -
Antibody–Drug Conjugates for the Treatment of Breast Cancer
by: Chiara Corti, et al.
Published: (2021-06-01) -
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
by: Bardia, A., et al.
Published: (2022) -
Antibody–Drug Conjugate to Treat Meningiomas
by: Kai Chen, et al.
Published: (2021-05-01) -
Marine Antibody–Drug Conjugates: Design Strategies and Research Progress
by: Yu-Jie Wang, et al.
Published: (2017-01-01)